U.S. Markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
129.55+0.45 (+0.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close129.10
Bid130.05 x 1800
Ask132.40 x 900
Day's Range128.43 - 131.54
52 Week Range127.80 - 189.00
Avg. Volume692,411
Market Cap7.37B
Beta (5Y Monthly)1.06
PE Ratio (TTM)30.70
EPS (TTM)4.22
Earnings DateNov 01, 2021 - Nov 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est207.82
  • Motley Fool

    September Sell-Off: 3 Dirt Cheap Growth Stocks to Buy

    September's been a rough month for the stock market, and on Monday, the S&P 500 had its worst day in months, falling 1.7%. Instead, it may be time to load up on three growth stocks near their 52-week lows, including Jazz Pharmaceuticals (NASDAQ: JAZZ), Activision Blizzard (NASDAQ: ATVI), and Alibaba Group Holding (NYSE: BABA). Healthcare company Jazz Pharmaceuticals is trading at around $130 and has been falling more than 20% year to date, while the S&P 500 has risen by 16%.

  • PR Newswire

    Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Xywav® (calcium, magnesium, potassium and sodium oxybates), the first and only U.S. Food and Drug Administration-approved treatment for idiopathic hypersomnia (IH) in adults, which was approved on August 12, 2021.

  • PR Newswire

    Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences: